Literature DB >> 7593455

Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus.

D B Thompson1, W S Samowitz, S Odelberg, R K Davis, J Szabo, H Heath.   

Abstract

Inactivating mutations of the parathyroid cell calcium receptor (CaR) gene cause one form of familial benign/hypocalciuric hypercalcemia, and in homozygous form, cause neonatal severe primary hyperparathyroidism with parathyroid hyperplasia. Thus, we postulated that partial or total loss of CaR function might contribute to calcium insensitivity or even stimulate cell proliferation in sporadic parathyroid adenomas (PAds). To examine this possibility, we sought loss of heterozygosity (LOH) for markers flanking the CaR locus (3cen-3q21) in 35 PAds. We used 16 highly-polymorphic PCR-based markers in paired normal and tumor DNA, extracted from slices of archived surgical specimens. Nineteen to 24 of the DNA pairs were informative with at least one marker. In two informative pairs, we found LOH for markers D3S1303, D3S1267, or D3S1269, which are tightly-linked with and flank the CaR locus. In one tumor, deletion mapping confined the lost area between D3S1271 and D3S1238 (41.7 centimorgans, cM). In the other tumor, LOH spanned most of chromosome 3, ranging at least from D3S1307 to D3S1311 (271.4 cM). LOH was confirmed by repetition of the experiments and quantified by phosphorimaging. Thus, we found LOH encompassing the CaR locus in approximately 10% of sporadic PAds. These data are consistent with the hypothesis that loss of CaR function may occur in PAds, with functional consequences for calcium sensitivity and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593455     DOI: 10.1210/jcem.80.11.7593455

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.

Authors:  S Hemmer; V M Wasenius; C Haglund; Y Zhu; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Molecular mechanisms of primary hyperparathyroidism.

Authors:  G N Hendy
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

3.  p53/MDM2 Pathway Aberrations in Parathyroid Tumors: p21(WAF-1) and MDM2 Are Frequently Overexpressed in Parathyroid Adenomas.

Authors:  Begona Arribas; Eva Cristobal; Jose A. Alcazar; Juan Tardio; Juan C. Matinez-Montero; Jose R. Polo; Rafael Carrion; Laura Gil; Marta Azanedo; Jose M. Rojas; Javier Menarguez
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

4.  Analysis of the Cycilin D1/p16/pRb Pathway in Parathyroid Adenomas.

Authors:  Eva Cristobal; Begona Arribas; Juan Tardio; Jose A. AIcazar; Juan C. Matinez-Montero; Rafael Carrion; Jose R. Polo; Laura Gil; Marta Azanedo; Jose M. Rojas; Javier Menarguez
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

5.  Clonal emergence in uremic parathyroid hyperplasia is not related to MEN1 gene abnormality.

Authors:  L Shan; Y Nakamura; M Murakami; M Nakamura; A Naito; K Kawahara; H Utsunomiya; I Mori; K Kakudo
Journal:  Jpn J Cancer Res       Date:  1999-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.